Preclinical studies have demonstrated that GPC3-targeting ADCs can effectively bind to HCC cells, induce internalization, and deliver cytotoxic payloads, resulting in significant anti-tumor activity in vitro and in vivo (71). The gene discussed is GPC3; the disease is neoplasm.